Evaluation of the toxic potentials of a new camptothecin anticancer agent CKD-602 on fertility and early embryonic development in rats (Q28249695)

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Properties of Sufficiency and Statistical Tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Toxicity patterns of cytotoxic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Evaluation of spermatogenesis and fertility in F1 male rats after in utero and neonatal exposure to extremely low frequency electromagnetic fields.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Reproductive endocrinology and toxicological pathology over the life span of the female rodent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

New Tables for Multiple Comparisons with a Control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Subchronic toxicity of plant sterol esters administered by gavage to Sprague-Dawley rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Effects of prenatal exposure to the environmental pollutant 2-bromopropane on embryo-fetal development in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

26-Week repeated oral dose toxicity study of the new quinolone antibacterial DW-116 in Sprague-Dawley rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Subacute toxicity evaluation of a new camptothecin anticancer agent CKD-602 administered by intravenous injection to rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

4-Week repeated intravenous dose toxicity study of a new camptothecin anticancer agent CKD-602 in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Evaluation of rodent sperm, vaginal cytology, and reproductive organ weight data from National Toxicology Program 13-week studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

In vitro pharmacodynamics of CKD-602 in HT-29 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Topoisomerase I inhibitors: review and update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

The current status of camptothecin analogues as antitumor agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004

Clinical applications of the camptothecins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.05.004